Stagg, John

Immune evasion in cancer: mechanistic basis and therapeutic strategies

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,625

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 1,407

The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets

Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews

Adenosine and Purinergic SignalingBiochemical and Molecular Research

Cited by 927

Consensus guidelines for the detection of immunogenic cell death

Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology

Immunotherapy and Immune ResponsesCell death mechanisms and regulation

Cited by 832

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers

Cited by 496

Immunosuppressive Activities of Adenosine in Cancer

Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology

Adenosine and Purinergic SignalingBiochemical and Molecular Research

Cited by 292